Caspofungin: New echinocandin antifungal agent;Caspofungine: Nouvel antifongique de la classe des échinocandines

Journal de Mycologie Medicale

Volumn 12, Issue 3 SUPPL., 2002, Pages

  Dupont, B ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Aspergillus; Candida; Candidemia; Caspofungin; Invasive aspergillosis

Indexed keywords

ALKALINE PHOSPHATASE; AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; CYTOCHROME P450; FLUCONAZOLE;

AIDS RELATED COMPLEX; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOLERANCE; ESOPHAGITIS; FEVER; HUMAN; NEUTROPENIA; SURVIVAL RATE; VEIN DISEASE;

EID: 0036741628     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Abruzzo GK, Gill Ch J, Flattery AM et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 2000;44:2310-8.
2. Arathoon EG, Gotuzzo E, Noriega M et al. Randomized, doubleblind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002;46:451-7.
3. st ICAAC Chicago, Illinois, Sept 22-25,2001. Abstract 571.
4. Arikan S, Lozano-Chiu M, Paetznick V et al. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001;45:327-30.
5. Arikan S, Lozano-Chiu M, Paetznick V et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002;46:245-7.
6. Barchiesi F, Schimizzi AM, Fothergill AW et al. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis 1999;18:302-4.
7. Bartizal K, Gill CJ, Abruzzo GK et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743, 872). Antimicrob Agents Chemother 1997;41:2326-32.
8. th Congress of Clinical Microbiology and infections diseases. Milan, Italy 2002, abstract n° 0237.
9. th ICAAC Toronto, Canada. Sept 19, 2000. Abstract 1683.
10. Gonzalez GM, Tijerina R, Najvar LK et al. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother 2001;45:1854-9.
11. st FOCUS on fungal infection 11, Washington DC 2001. Abstract 22.
12. Hossain M, Ghannoum M., Sheehan D. In vitro combination of voriconazole with caspofungin against pathogenic fungi. TIFI 6. Prague, Czech Republic. Oct 18-20,2001. Abstract P 59.
13. Houang A. Caspofungin acetate: an antifungal agent. Am J Health Sys Pharm 2001;58:1206-14.
14. Keating GM, Jarvis B. Caspofungin. Drugs 2001;61:1121-9.
15. Kurtz MB, Abruzzo G, Flattery A et al. Characterization of echinocandin-resistant mutants of Candida albicans: Genetic, biochemical, and virulences studies. Infection and immunity 1996;64:3244-51.
16. Lozano-Chiu M, Nelson PW, Paetznick VL et al. Disk diffusion method for determining susceptibilities of Candida spp to MK-0991. J Clin Microbiol 1999;37:1625-7.
17. Pfaller MA, Messer SA, Gee S et al. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol 1999;3;7:870-2.
18. Pfaller MA, Messer SA, Mills K et al. Evaluation of etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J Clin Microbiol 2001;39:4387-9.
19. st ICAAC Chicago, Illinois. Sept 22-25, 2001 Abstract J-105.
20. st ICAAC Toronto, Canada. Sept 17 2000. Abstract 193.
21. Stone JA, Holland SD, Wickersham PJ et al. Single and multiple. dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002;46:739-45.
22. st ICAAC Chicago, Illinois, Sept. 22-25, 2001.
23. Villanueva A, Arathoon EG, Gotuzzo E et al. A randomized double. blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001;33:1529-35.